Compare KraneShares CSI China Internet ETF (KWEB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Smith & Nephew plc — how do they compare? KraneShares CSI China Internet ETF trades at $24.9 (market cap $4.37B), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.5× KraneShares CSI China Internet ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Smith & Nephew plc for 121 Days on average.
| KWEB | SNN | |
|---|---|---|
Market Cap | $4.37B | $11.10B |
Volume | 13,393,361 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $37.17 |
52-Week Low | $23.63 | $26.42 |
Typical Hold Time | 57 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.87, up 2.22% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell, while oscillators are neutral. Recent news highlights institutional activity, including a stake reduction by Tidal Investments LLC and an increase by HSBC Holdings PLC, amid ongoing U.S.-China trade dynamics and economic data releases.
The outlook for KWEB is clouded by geopolitical tensions and economic headwinds in China, though corporate profit growth offers a potential catalyst. Key risks include trade policy shifts and weak domestic consumption. Investors should weigh institutional movements against broader market sentiment for balanced exposure.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
